DCTH Live signals | Maximize Profits with Getagraph.com

BUY 104182 min ago

@ $4.59

Issued: 13 Feb 2024 @ 09:32

Return: 14.60%

Previous signal: Feb 6 - 10:18

Previous signal: Sell

Return: -0.33 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe...

Stats
Today's Volume	146 954
Average Volume	214 390
Market Cap	129.20M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $-0.430 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.790
ATR14	$0.0100 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-19	Aharon Gil	Buy	26 882	Common Shares
2024-03-19	Salamon Steven A J	Buy	26 882	Common Shares
2024-03-19	Rosalind Advisors, Inc.	Buy	619 946	Pre-funded Warrants
2024-03-18	Rook Martha S.	Buy	125 000	Employee Stock Option (Right to Buy)
2024-03-18	Rook Martha S.	Buy	0

INSIDER POWER
93.86
Last 96 transactions
Buy: 8 343 756 \| Sell: 533 108

Volume Correlation

Long: -0.08 (neutral)

Short: -0.61 (weak negative)

Signal:(40.14) Neutral

Delcath Systems Inc Correlation

10 Most Positive Correlations
META	0.947
JBSS	0.939
MANH	0.938
DSGX	0.937
CIFR	0.933
INOD	0.932
NVCT	0.932
ASO	0.932
IOAC	0.932
LIBY	0.931

10 Most Negative Correlations
NCBS	-0.944
TSHA	-0.922
BWB	-0.915
GSMG	-0.915
IPA	-0.911
ALRS	-0.903
HLIO	-0.902
COFS	-0.901
CYRN	-0.9
GXGX	-0.899

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Delcath Systems Inc Correlation - Currency/Commodity

0.00
( neutral )

-0.07
( neutral )

0.00
( neutral )

0.49
( neutral )

0.00
( neutral )

-0.33
( neutral )

Delcath Systems Inc Financials

Annual	2023
Revenue:	$2.07M
Gross Profit:	$1.30M (63.05 %)
EPS:	$-2.94

Q4	2023
Revenue:	$539 000
Gross Profit:	$327 000 (60.67 %)
EPS:	$-0.480

Q3	2023
Revenue:	$434 000
Gross Profit:	$301 000 (69.35 %)
EPS:	$-1.140

Q2	2023
Revenue:	$495 000
Gross Profit:	$345 000 (69.70 %)
EPS:	$-0.580

Financial Reports:

No articles found.

Delcath Systems Inc

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.